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Abstract
Background: Tetrabenazine is a monoamine depleter with a well-documented effect against chorea associated with Huntington disease (HD). There is a paucity
of data about how reduction in chorea relates to better performance on motor, gait, cognitive, and psychiatric assessments.
Methods: We designed an open label tetrabenazine withdrawal study to test performance using validated scales. The following instruments were used to assess
cognitive, behavioral, and motor function in 10 patients with documented HD: The Montreal Cognitive Assessment, Beck Depression Inventory II, Dynamic Gait
Index (DGI), Jebsen Hand Test, Timed 25-foot walk, Berg Balance Test (BBT), QuickDASH, and the Unified Huntington Disease Rating Scale (UHDRS) Motor,
Stroop Color Word, Behavioral Assessment, Functional Checklist, and Independence Scale.
Results: Subjects performed significantly better while on tetrabenazine as measured by the DGI (p50.041), BBT (p50.007), and the UHDRS Total Motor
(p50.009), Maximum Chorea (p50.005), and Stroop Color-Word tests (p50.028).
Discussion: This pilot study demonstrates tetrabenazine’s potential effects beyond improvement in chorea.
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Introduction
Tetrabenazine is a monoamine-depleting drug, which was
originally developed for the treatment of schizophrenia and has been
successfully used for the treatment of a variety of hyperkinetic
movement disorders.1,2 A benzoquinolizine derivative of reserpine,
tetrabenazine acts by reversibly inhibiting vesicular monoamine
transporter type 2 (VMAT2). The effect of tetrabenazine on
reduction of chorea in Huntington disease (HD) is well documented.3
There is a paucity of data, however, on how reduction of chorea
impacts motor performance and overall function, including activities
of daily living. One study, involving 13 HD patients treated with
haloperidol, showed improvement of chorea but not of gait.4
Olanzapine treatment in HD patients showed a 35% improvement
in gait, tandem gait, and pull test subscores of the Unified Huntington
Disease Rating Scale (UHDRS).5 In another study, involving 11
patients with HD, tetrabenazine was associated with improvement in
lifting of large, light objects.6
We designed a study to measure the functional effects of
tetrabenazine on various cognitive, behavioral, and motor domains
using validated scales.
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Methods
Patients with a definite diagnosis of HD and on a stable dose of
tetrabenazine for at least 3 months were recruited for the study from
the Baylor Parkinson’s Disease Center and Movement Disorders
Clinic (PDCMDC). Written informed consent, approved by the
Institutional Review Board of Baylor College of Medicine, was
obtained prior to commencement of the study. The enrolled patients
were first evaluated within 3 hours of taking the usual, stable morning
dose of tetrabenazine (ON evaluation). They were then instructed to
stop taking tetrabenazine and were re-evaluated with the same battery
of tests 3–4 days later (OFF evaluation), after which time their usual
dose of tetrabenazine was restarted. The inclusion criteria were 1)
diagnosis of definite HD by a movement disorders expert confirmed by
HD gene CAG repeat length greater than 40, and 2) ability to walk
independently or with minimal assistance such as with the use of a
cane or walker in the ON tetrabenazine state. Patients who were non-
ambulatory or required assistance to ambulate even in the ON state
and those with psychiatric symptoms that would interfere with their
full compliance with our instructions and testing were excluded.
After obtaining demographic information the subjects were tested
using the following scales.
1) Montreal Cognitive Assessment (MoCA), a brief screening
instrument for early cognitive impairment (range 0–30, high
score5normal).7
2) Beck Depression Inventory-II (BDI-II), a validated scale of
depressive symptoms (range 0–63, high score5impaired).8
3) Unified Huntington Disease Rating Scale (UHDRS), a clinical
examination of motor and cognitive features commonly seen in
HD (UHDRS motor range 0–124, high score5impaired,
UHDRS-2 Stroop Color Word Interference calculated score,
high score5normal, UHDRS-3 Behavioral Assessment fre-
quency and severity weighted score, high score5impaired,
UHDRS-4 Functional Checklist Range 0–25, high score5im-
paired, UHDRS-5 Independence Scale Range 0–100, high
score5normal).9
4) Berg Balance Test (BBT), a 14-item assessment of sitting,
standing, transferring, and turning. Each task is rated on a scale
of 0–4 (range 0–56, high score5normal).This scale has been
validated in the elderly population and in those with acute
stroke.10,11
5) Timed 25-foot walk (T25-FW), which consists of two timed trials
of walking through a 25-foot course and was developed for the
Multiple Sclerosis Functional Composite (scored as time to
complete task, high score5impaired).12
6) Jebsen–Taylor Hand Function Test (JTHFT), a seven-item test
designed to provide an objective measure of various aspects of
hand function. Participants are timed performing common
functional activities: writing, card turning (simulated page
turning), picking up small common objects, simulated feeding,
stacking checkers, lifting light cans, and lifting weighted cans
(scored as total time to complete tasks, high score5impaired).13
7) Quick DASH, a self-report questionnaire consisting of 11
questions regarding upper extremity function (range 0–100,
high score5impaired).14
8) Dynamic Gait Index (DGI), a gait examination that is rated on a
four-point scale for each of eight conditions including stepping
over an obstacle (range 0–24, high score5normal).15
Gait, hand function, and UHDRS motor assessments were
performed by one of the authors (R.F.). Cognitive and psychiatric
tests were performed by trained study coordinators. Each evaluation
lasted approximately 90 minutes.
We applied parametric analyses to the summation of the individual
ordinal scores, and non-parametric analysis using the Wilcoxon
matched-pairs signed-rank test was applied for those tests whose
primary measures were ordinal and those with interval-type data.
Normality of distributions was tested using the Stata function sktest,
looking at skewness and kurtosis, then both were combined. Summary
data scores for each of the instruments administered were tested for
equality of variance with a 95% confidence interval between the off-
and on-drug state to confirm appropriateness of matched-pairs
analysis. Statistical data analysis was performed using Stata/IC 11.2
for Windows (College Station, Texas). Analyses were re-run using non-
parametric tests, with no difference in the outcome of significance.
Results
A total of 10 patients (60% female with a mean age of 58¡11 years
and duration of motor symptoms for a mean of 8¡3.5 years) were
recruited. The study was performed over a 14-month period (March
2010 to May 2011). No subjects were excluded. The average CAG
repeat number for nine patients was 43¡2; one was reported to have
greater than 40 CAG repeats, but the exact number was not available.
Statistically significant deterioration in BBT, DGI, and UHDRS
Total Motor, Maximum Chorea, and UHDRS Stroop Color-Word
scores were observed after withdrawal of tetrabenazine, suggesting that
tetrabenazine treatment improves not only chorea but also gait and
balance, as suggested by deterioration in BBT and DGI scores when
tetrabenazine was withdrawn. No significant change was noted in
other measures of function, such as JTHFT and Quick DASH, or in
cognitive and behavioral measures such as MoCA and BDI-II scores
(Table 1). The change in UHDRS Total Motor score (TMS) was
driven by a substantial increase in the chorea scores in the OFF
condition, as TMS change with chorea questions excluded was not
significant (z520.873, probability . |z| 5 0.3829).
There were no adverse events reported from withdrawal of
tetrabenazine except, as expected, worsening of chorea.
Discussion
Our study showed that tetrabenazine, a VMAT2 inhibitor, has
beneficial effects not only on chorea, consistent with previously
published open label and randomized control studies,1–3 but also on
gait and balance. Significantly better BBT and DGI scores with
tetrabenazine suggest that improvement in chorea translates into
reduced interference with the normal cadence and other components
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Table 1. Study Results
Variable On/Off Mean (¡SD) 95% CI z1 Probability .|z|
MoCA (total) Off 19.95 (5.56) 16.8–23.2
On 20.0 (4.50) 17.4–22.6 0.531 0.595
Dynamic Gait Index (total) Off 14.4 (7.01) 9.38–19.42
On 17.5 (6.94 12.53–22.47 2.045 0.0412
Berg Balance Scale (total) Off 40.9 (9.67) 33.99–47.81
On 46.5 (6.06) 42.17–50.83 2.68 0.0072
Jebsen Hand Test (total)
(non-dominant)
Off 193.1 (111.6) 113.2–272.9
On 217.3 (111.3) 137.7–296.9 1.070 0.285
Jebsen Hand Test (total)
(dominant)
Off 131.2 (73.3) 78.8–183.6
On 125.0 (57.1) 84.1–165.8 20.459 0.647
Timed 25-foot Walk
(average, two trials)
Off 8.5 (3.6) 5.9–11.1
On 8.1 (2.1) 6.6–9.5 .0153 0.879
Beck Depression Inventory
II (total)
Off 12.8 (9.7) 5.9–19.7
On 10.4 (6.7) 5.6–15.2 21.436 0.151
QuickDASH (disability/
symptom score)
Off 43.2 (27.5) 23.5–62.8
On 37.3 (26.5) 18.3–56.2 21.02 0.307
UHDRS-1 Motor (total
motor score)
Off 45.4 (10.4) 38.0–52.8
On 36.1 (15.7) 24.9–47.3 22.609 0.0092
UHDRS-1 Motor (max
chorea)
Off 18.4 (2.5) 16.6–20.2
On 10.8 (5.5) 6.9–14.7 22.814 0.0052
UHDRS-1 Motor total
motor – max chorea
Off 27.0 (9.9) 19.9–34.1
On 25.3 (12.4) 16.5–34.1 20.873 0.383
UHDRS-2 Cognition:
Stroop Color-Word26
Off 7.72 (7.5) .67–12.5
On 14.3 (3.6) 11.5–17.1 2.191 0.0282
UHDRS-3 Behavior:
Frequency and Severity
Off 9.3 (10.5) 4.5–22.3
On 13.4 (12.5) 1.8–16.8 1.298 0.194
UHDRS-4 Functional
Checklist
Off 15.2 (5.3) 11.4–19.0




On 74.5(13.0) 65.2–83.8 0.0623
1Wilcoxon matched-pairs signed-rank test.
2Statistically significant result.
3Two tailed paired Student’s t-test.
Abbreviations: CI, confidence interval; MoCA, Montreal Cognitive Assessment; SD, standard deviation; UHDRS, Unified Huntington Disease Rating Scale.
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of gait and with maintenance of posture and balance. Posturography
studies have shown that patients with HD are unable to properly focus
on vestibular information while gating out erroneous visual and
proprioceptive cues.16 Indeed, postural instability has been suggested
as a marker for pre-clinical HD.17 A possible explanation for
improvement of the BBT and DGI scores is improvement in gating
out of abnormal sensory cues, analogous to significant improvement in
gating out abnormal information in the Stroop Color Word
interference test, which was also significantly improved with
tetrabenazine in this sample. Improvement in Stroop performance
after dopamine depletion was previously reported.18 The BBT and
DGI measured not only ambulation in a straight line as the T25-FW,
but also include other activities such as transferring and stepping over
obstacles, which could explain the difference in significance between
the T25-FW versus BBT and DGI.
We were not able to demonstrate better fine motor function with
tetrabenazine. Furthermore, performance on fine motor tasks, as
measured by JTHFT and Quick DASH, or speed of gait, as measured
by T25-FW, may have been hampered by underlying bradykinesia,
well documented in HD,19 or dysfunction in error feedback control of
movements.20 Depression did not improve after short-term tetra-
benazine withdrawal.
Withdrawal as opposed to de novo study design introduces additional
considerations for our study. Tetrabenazine will have ‘‘disappeared
from most tissues, brain tissues included’’ after 24 hours.2,21 The active
metabolite, alpha-dihydrotetrabenazine, has a half-life of 7 hours.
Based on another tetrabenazine withdrawal study, there was no
statistically significant difference in chorea scores between the third
and fifth day after tetrabenazine withdrawal.22 In addition, there was
no significant difference in post-withdrawal chorea scores compared
with baseline after 80 weeks of tetrabenazine treatment in the
TETRA-HD continuation study.23 There is the possibility of a long-
term effect of tetrabenazine on histological changes in the substantia
nigra24 and on serotonin and alpha-1-adrenergic receptor density25 as
well as other pharmacological effects, which may confound our
findings.2
Interpretations of the results of our study are limited because of the
open label design and a small sample size. Small sample size is partly
due to marked difficulties recruiting for this study as it involved
withdrawal of tetrabenazine and tedious evaluation, which took several
hours to complete. The presence of some nocebo effect is a possibility
given the open label design of the study.
Nevertheless, despite these limitations, we believe this pilot study
demonstrates tetrabenazine’s potential effects beyond improvement in
chorea.
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